Literature DB >> 12894509

EGFR but not PDGFR-beta expression correlates to the antiproliferative effect of growth factor withdrawal in glioblastoma multiforme cell lines.

Marc-E Halatsch1, Esther Gehrke, Farhad A Borhani, Thomas Efferth, Carola Werner, Panos Nomikos, Ursula Schmidt, Michael Buchfelder.   

Abstract

BACKGROUND: The aim of the current study was to investigate a putative relationship between (i) growth characteristics (proliferation and tumorigenicity) of nine glioblastoma multiforme (GBM) cell lines under different growth-stimulating conditions in vitro and (ii) their basal expression of a panel of growth factor receptors/autocrine cytokines.
MATERIALS AND METHODS: Basal expressions of the epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor-beta (PDGFR-beta), platelet-derived growth factor-AA (PDGF-AA) and PDGF-BB, tumor growth factor-alpha (TGF-alpha) and TGF-beta as well as tumor necrosis factor-alpha (TNF-alpha) were determined by immunocytochemistry at standard cell culture conditions (10% fetal calf serum [FCS]). Proliferation and tumorigenicity at 10% FCS and relative serum starvation (0.5% FCS) were assessed by using Coulter counting and soft agar cloning, respectively.
RESULTS: The ratio between cell multiplications at 10% and 0.5% FCS over a 10-day period was defined as a measure of growth factor dependence of cellular proliferation. Expression of EGFR (but not of PDGFR-beta) strongly correlated to this ratio (Spearman rank correlation coefficient R = 0.87). No considerable correlations were present among other appropriate pairs of variables with biologically founded putative relationships.
CONCLUSION: Greater expression of EGFR is associated with increased growth factor dependence of cellular proliferation. Our results strengthen the role of EGFR as a rational molecular target of therapeutic intervention in GBM.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12894509

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.

Authors:  David M Peereboom; Manmeet S Ahluwalia; Xiaobu Ye; Jeffrey G Supko; Sarah L Hilderbrand; Surasak Phuphanich; L Burt Nabors; Myrna R Rosenfeld; Tom Mikkelsen; Stuart A Grossman
Journal:  Neuro Oncol       Date:  2013-01-17       Impact factor: 12.300

2.  IGFBP2 is overexpressed by pediatric malignant astrocytomas and induces the repair enzyme DNA-PK.

Authors:  Oren J Becher; Katia M Peterson; Soumen Khatua; Maria R Santi; Tobey J MacDonald
Journal:  J Child Neurol       Date:  2008-10       Impact factor: 1.987

Review 3.  HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme.

Authors:  Jeffrey J Raizer
Journal:  J Neurooncol       Date:  2005-08       Impact factor: 4.130

4.  Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme.

Authors:  David M Peereboom; Dale R Shepard; Manmeet S Ahluwalia; Cathy J Brewer; Neeraj Agarwal; Glen H J Stevens; John H Suh; Steven A Toms; Michael A Vogelbaum; Robert J Weil; Paul Elson; Gene H Barnett
Journal:  J Neurooncol       Date:  2009-12-04       Impact factor: 4.130

5.  Robust detection of EGFR copy number changes and EGFR variant III: technical aspects and relevance for glioma diagnostics.

Authors:  Judith Jeuken; Angelique Sijben; Cristina Alenda; Jos Rijntjes; Marieke Dekkers; Sandra Boots-Sprenger; Roger McLendon; Pieter Wesseling
Journal:  Brain Pathol       Date:  2009-10       Impact factor: 6.508

6.  Tyrosine phosphorylation of the human glutathione S-transferase P1 by epidermal growth factor receptor.

Authors:  Tatsunori Okamura; Simendra Singh; John Buolamwini; Timothy Haystead; Henry Friedman; Darell Bigner; Francis Ali-Osman
Journal:  J Biol Chem       Date:  2009-03-02       Impact factor: 5.157

Review 7.  Incorporating molecular tools into early-stage clinical trials.

Authors:  Robert J Weil
Journal:  PLoS Med       Date:  2008-01-22       Impact factor: 11.069

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.